Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2006-09-05
2006-09-05
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S660000
Reexamination Certificate
active
07101916
ABSTRACT:
A pharmaceutical composition includes a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of exo-R-mecamylamine in combination with a pharmaceutically acceptable carrier. Preferably the amount is about 0.5 mg to about 20 mg. Medical conditions are treated by administering a therapeutically effective amount of exo-S-mecamylamine or a pharmaceutically acceptable salt thereof, substantially free of its exo-R-mecamylamine, said amount being sufficient to ameliorate the medical condition. The medical conditions include but are not limited to substance addiction (involving nicotine, cocaine, alcohol, amphetamine, opiate, other psychostimulant and a combination thereof), aiding smoking cessation, treating weight gain associated with smoking cessation, hypertension, hypertensive crisis, Tourette's Syndrome and other tremors, cancer (such as small cell lung cancer), atherogenic profile, neuropsychiatric disorders (such as bipolar disorder, depressoin, an anxiety disorder, schizophrenia, a seizure disorder, Parkinson's disease and attention deficit hyperactivity disorder), chronic fatigue syndrome, Crohn's disease, autonomic dysreflexia, and spasmogenic intestinal disorders.
REFERENCES:
patent: 5039801 (1991-08-01), Brossi et al.
patent: 5686448 (1997-11-01), Baldone
patent: 5986142 (1999-11-01), Magni et al.
patent: 6034079 (2000-03-01), Sanberg et al.
patent: 6121289 (2000-09-01), Houdi
patent: 6197827 (2001-03-01), Cary
patent: 6734215 (2004-05-01), Shytle et al.
Solomons, Organic Chemistry, 3RDEdition, p. 419, 1984.
Gardiner, Mark R., “Genetic Basis of the Human Epilepsies,”Epilepsy Research 36: 91-95 (1999).
Goodman, Elizabeth, et al., “Depressive Symptoms and Cigarette Smoking Among Teens,”Pediatrics 106(4): 748-755 (Oct. 2000).
Hennings, Esteban C.P., et al., “Nicotinic Acetylcholine Receptor Antagonistic Activity of Monoamine Uptake Blockers in Rat Hippocampal Slices,”J. Neurochem.73: 1043-1050 (1999).
Martin, Thomas J., et al., “Pharmacological Evaluation of the Antagonism of Nicotine's Central Effects by Mecamylamine and Pempidine,”J.P.E.T. 254(1): 45-51 (1990).
Papke, Roger L., et al., “Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes,”J.P.E.T. 297(2): 646-656 (2001).
Schonenberger, Bernhard, et al., “Preparation of Optically Active Secondary Amines by Thermal Decomposition of (Methylbenzyl)urea Analogs: Absolute Configuration of (+) and (−) Mecamylamine,”Helvetica Chimica Acta 69: 283-287 (1986).
Stone, Clement A., et al., “Chemistry and Structure-Activity Relationships of Mecamylamine and Derivatives,”J. Med.Pharm. Chem. 5(4): 665-690 (1962).
Suchocki, John A., et al., “Synthesis of 2-exo- and 2-endo-Mecamylamine Analogues. Structure-Activity Relationship for Nicotinic Antagonism in the Central Nervous System,”J. Med. Chem. 34: 1003-1010 (1991).
Tattersall, F.D., et al., “Enantiospecific Inhibition of Emesis Induced by Nicotine in the House Musk Shrew (Suncus murinus) by the Neurokinin1(NK1) Receptor Antagonist CP-99,994,”Neuropharmacol. 4(12): 1697-1699 (1995).
Newman Mary
Sanberg Paul
Shytle Douglas
Silver Archie A.
Jones Dwayne
University of South Florida
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Exo-S-mecamylamine formulation and use in treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Exo-S-mecamylamine formulation and use in treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Exo-S-mecamylamine formulation and use in treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3528196